IGF1 and asphyxia: Depending on the way and mode of the IGF-1 administration (for instance intraventricular versus intranasal or subcutaneous, in one or several repeated doses, within narrow therapeutic window or after the onset of first neurological symptoms, alone, or combined with other therapy etc.), different beneficial effects have been reported in animal models of birth asphyxia.